Precision Diabetes, Inc.
Precision Diabetes, Inc.

Precision Diabetes

Precision DiabetesPrecision DiabetesPrecision Diabetes

An emerging leader in enabling precision medicine for diabetes through the use of novel diabetes biomarkers and algorithms 

Our Diabetes Solution

GlycoMark®

DIABETESpredict

DIABETESpredict

An FDA-cleared and CE-Marked blood test specific to detecting recent hyperglycemia and glycemic variabilities

DIABETESpredict

DIABETESpredict

DIABETESpredict

CE-Marked genetic assessment of type 2 diabetes risk 


Product website:

http://www.patiadiabetes.com/en/  

GDMpredict

DIABETESpredict

Precision IGT (NEW TEST)

CE-Marked genetic assessment of gestational diabetes risk


Product website: http://www.patiadiabetes.com/en/patia/products/gdmpredict/  

Precision IGT (NEW TEST)

AutoDx (Integrated Point-Of-Care Testing System)

Precision IGT (NEW TEST)

A simple blood test that predicts 1-hour glucose levels (OGTT) and early-phase-beta-cell dysfunction 

AutoDx (Integrated Point-Of-Care Testing System)

AutoDx (Integrated Point-Of-Care Testing System)

AutoDx (Integrated Point-Of-Care Testing System)

CE-Marked 1-STEP convenience for POCT

-  SARS-CoV-2 antigen

-  SARS-CoV-2 antibody

- Hemoglobin A1c

- CRP

- U-Albumin

- Glycated Albumin

- Influenza A and B (coming soon)

Coronavirus and Diabetes

The dangerous interaction between COVID-19 and type 2 diabetes

Type 2 diabetes is associated with an increased risk of serious complications or death if you get CORONAVIRUS. Observational data indicate that patients with diabetes are at greater risk of SARS-CoV-2 infection, serious illness and death from COVID-19 than patients without diabetes. Preventing type 2 diabetes and controlling hyperglycemia helps to avoid the fatal consequences of coronavirus. The death rate in patients with COVID-19 who have hyperglycemia is 7 times higher. It is possible to act against the dramatic consequences of the interaction between these two pandemics: COVID-19 and type 2 diabetes.


http://www.patiadiabetes.com/en/covid-19-diabetes-the-dangerous-interaction-of-two-pandemics/ 

PRECision diabetes news

Predicting COVID19 Patient Mortality: 1,5-anhydroglucitol Test More Accurate than HbA1c + Glucose

"This week, Precision Diabetes, Inc. presented data demonstrating that the 1,5-anhydroglucitol blood test (GlycoMark®) is more accurate than commonly used diabetes tests in predicting mortality in hospitalized COVID-19 patients with and without diabetes." (November 2021, Endocrine News)

Press Release

New Late-Breaking Data at The ADA Show GlycoMark® May Be an Effective Test for COVID-19 Severity

Press Release

Precision Diabetes, Inc. Presents Data on Precision IGT Prediabetes Test at 2021 Conference

Press Release

Patia and Precision Diabetes, Inc. Announce New Strategic Collaboration

Press release

New Study Suggests GlycoMark May Identify Highest Risk Patients with Diabetes

Press Release

Newsletter Sign Up

Subscribe now and receive all the latest Precision Diabetes News!

Contact Us

Precision Diabetes, Inc.

2474 Walnut Street Box 168

Cary, NC 27518 USA

NY Office

500 7th Avenue 8th Floor New York, NY 10018 USA

info@precisiondiabetesinc.com 1-888-744-0221 1-919-390-1391

Office Hours

Monday - Friday: 9:00am - 5:00pm ET

Saturday - Sunday: Close

contact us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Social Media

Copyright © 2020 Precsion Diabetes, Inc. - All Rights Reserved.